Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers

Minerva Chirurgica

Volumn 58, Issue 3, 2003, Pages 297-303

  Cheung, K L ^a   Robertson, J F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Biological markers; Breast neoplasms, diagnosis; Breast neoplasms, secondary; Breast neoplasms, therapy

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN 1; PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

BONE METASTASIS; BREAST METASTASIS; BREAST TUMOR; CANCER GROWTH; CANCER REGRESSION; CORRELATION ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MEDICAL ASSESSMENT; RADIODIAGNOSIS; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; VALIDATION PROCESS;

BREAST NEOPLASMS; DISEASE PROGRESSION; FORECASTING; HUMANS; NEOPLASM METASTASIS; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0142153404     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Hayward JL, Carbone PP, Heuson JC. Assessment of response to therapy in advanced breast cancer. Cancer 1977;39:1289-94.
2. Hayes DF, Zurawski VR, Kufe DW. Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986;10:1542-50.
3. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R et al. Circulating CA15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 1989;13:123-33.
4. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989;64:1674-81.
5. Robertson JFR, Pearson D, Price MR, Selby C, Badley RA, Pearson J et al. Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 1990;26:1127-32.
6. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M et al. Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995;36:41-8.
7. van Dalen A. New markers for breast carcinoma-associated antigen in comparison with CA15.3. Anticancer Res 1996;16:2339-43.
8. Reddish MA, Helbrecht N, Almeida AF. Epitope mapping of Mab B27.29 within the protein core of the malignant breast carcinoma-associated mucin antigen, MUC1. J Tumor Marker Oncol 1992;7:19-27.
9. Graves R, Hilgers J, Fritsche H. MUC1 mucin assays for monitoring therapy in metastatic breast cancer. Breast 1998;7:181-6.
10. Gold P, Freeman SO. Specific carcinoembryonic antigen of the human digestive system. J Exp Med 1965;122:467-81.
11. Go VLW, Zamcheck N. The role of tumor markers in the management of colorectal cancer. Cancer 1982;50(11 Suppl.):2618-23.
12. Lahousen M, Stettner H, Pickel H, Urdl W, Purstner P. The predictive value of a combination of tumor markers in monitoring patients with ovarian cancer. Cancer 1987;60:2228-32.
13. Sikorska H, Shuster J, Gold P. Clinical applications of carcinoembryonic antigen. Cancer Detect Pre 1988;12:321-55.
14. McNeely MDD. Gastrointestinal function and digestive disease. In: Kaplan LA, Pesc AJ, editors. Clinical Chemistry: Theory, Analysis, and Correlation. 2nd ed. St Louis: CV Mosby; 1989. p.411-2.
15. Fletchr RH. Carcinoembryonic antigen. Ann Intern Med 1986;104:66-73.
16. Mughal AW, Hortogagyi GN, Fritsche HA, Buzdar AU, Yap HY, Blumenschein GR. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA 1983;249:1881-6.
17. Williams MR, Turkes A, Pearson D, Twining P, Griffiths K, Blamey RW. The use of serum carcinoembryonic antigen to assess therapeutic response in locally advanced and metastatic breast cancer: a prospective study with external review. Eur J Surg Oncol 1988;14:417-22.
18. Robertson JFR, Pearson D, Price MR, Selby C, Pearson J, Blamey RW et al. Prospective assessment of the role of five tumour markers in breast cancer. Cancer Immunol Immunother 1991;33:403-10.
19. Williams MR, Turkes A, Pearson D, Griffiths K, Blamey RW. An objective biochemical assessment of therapeutic response in metastatic breast cancer: a study with external review of clinical data. Br J Cancer 1990;61:126-32.
20. Dixon AR, Jönrup I, Jackson L, Chan SY, Badley RA, Blamey RW. Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15-3: Fact or fiction? Dis Markers 1991;9:167-74
21. Dixon AR, Jackson L, Chan SY, Badley RA, Blamey RW. Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer 1993;68:181-5.
22. Robertson JFR, Pearson D, Price MR, Selby C, Blamey RW, Howell A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 1991;64:757-63.
23. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA15.3 and carcinoembryonic antigen in monitoring of the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-12.
24. Safi F, Kohler I, Röttinger E, Beger H. The value of the tumour marker CA15.3 in diagnosing and monitoring breast cancer. Cancer 1991;68:574-82.
25. Coveney EC, Geraghty JG, Sherry F, McDermott EW, Fennelly JJ, O'Higgens NJ et al. The clinical value of CEA and CA15.3 in breast cancer management. Int J Biol Markers 1995;10:35-41.
26. Pons-Anicet DMF, Krebs BP, Namer M. Value of CA15.3 in the follow-up of breast cancer patients. Br J Surg 1987;55:567-9.
27. Haagensen DE, Kister SJ, Vandevoorde JP, Gates JB, Smart EK, Hansen HJ et al. Evaluation of carcinoembryonic antigen as a plasma monitor for human breast carcinoma. Cancer 1978;42:1512-9.
28. Lokich JJ, Zamcheck N, Lowenstein M. Sequential carcinoembryonic antigen levels in the therapy of metastatic breast cancer. Ann Int Med 1978;89:902-6.
29. Doyle PJ, Nicholson RI, Groome GV, Blamey RW. Carcinoembryonic antigen (CEA): its role as a tumour marker in breast cancer. Clin Oncol 1981;7:53-8.
30. Lee YN. Serial tests of carcinoembryonic antigen in patients with breast cancer. Am J Clin Oncol 1983;6:287-93.
31. Dixon AR. Tumour markers - A logical approach to the guidance of therapy in advanced breast cancer? Doctor of Medicine Thesis, University of Nottingham; 1991.
32. Iwase H, Kobayashi S, Itoh Y. Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer. Breast Cancer Res Treat 1994;33:83-8.
33. Breast Specialty Group of the British Association of Surgical Oncology. The guidelines for the management of metastatic bone disease in breast cancer in the United Kingdom. Eur J Surg Oncol 1999;25:3-23.
34. Robertson JFR, Whynes DK, Dixon A, Blamey RW. Potential for cost economies in guiding therapy in patients with metastatic breast cancer. Br J Cancer 1995;72:174-7.
35. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
36. Cheung KL, Evans AJ, Robertson JFR. The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy. Breast Cancer Res Treat 2001;67:273-8.
37. Whitlock JPL, Evans AJ, Jackson L, Chan SY, Robertson JF. Imaging of metastatic breast cancer: Distribution and radiological assessment of involved sites at presentation. Clin Oncol 2001;13:181-6.
38. Jäger W, Merkle E, Lang N. Increasing serum tumour markers as decision criteria for hormone-therapy of metastatic breast cancer. Tumour Biol 1994;12:60-6.
39. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by "early" salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997;76:1106-11.
40. Cheung KL, Pinder SE, Paish C, Sadozye AH, Chan SY, Evans AJ et al. The role of blood tumour marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer. Int J Biol Markers 2000;15:203-9.